Merck & Co., Inc. (MRK) stock price, news and key stats

Price

Last close as of Sep 16, 2026. Delayed data; not a live quote.

Previous close

$143.79

Open

$143.96

Day range

$143.50 – $144.97

Volume

7.2M

About Merck & Co., Inc.

Latest MRK news

• Vital Signs: Novartis' mounting M&A headaches
  IPO & M&A · Sep 13, 2026

  Novartis is facing increasing challenges in its mergers and acquisitions (M&A) strategy, as the pharmaceutical giant grapples with regulatory scrutiny and integration issues from recent deals. The company's attempts to bolster its pipeline through acquisitions have been met with skepticism from investors, particularly in light of the complexities involved in assimilating new assets and aligning them with its existing operations. This has raised concerns about the potential for value dilution and the effectiveness of Novartis' long-term growth strategy. Market analysts are closely monitoring Novartis' stock performance in response to these challenges. The company's shares have shown volatility, reflecting investor apprehension regarding its ability to successfully navigate the M&A landscape. Furthermore, the broader pharmaceutical sector is experiencing heightened competition and regulatory pressures, which could exacerbate Novartis' difficulties in executing future transactions. As the company seeks to reassure stakeholders, it may need to adopt a more cautious approach to M&A, focusing on organic growth and innovation rather than aggressive acquisitions.

• Triad experts weigh in on the Canadian and US trade war and how it could affect pharmaceuticals
  Geopolitics · Sep 11, 2026

  The ongoing trade tensions between Canada and the United States are raising concerns among industry experts regarding their potential impact on the pharmaceutical sector. As both nations grapple with tariffs and regulatory barriers, the implications for drug pricing, supply chains, and research collaboration are becoming increasingly pronounced. Experts warn that heightened trade disputes could lead to increased costs for pharmaceutical companies, which may ultimately be passed on to consumers in the form of higher drug prices. Moreover, the trade war could disrupt the intricate supply chains that underpin the pharmaceutical industry. Canada is a significant player in the production of active pharmaceutical ingredients (APIs) and generic drugs, and any restrictions on trade could hinder the availability of these essential components in the U.S. market. This disruption could lead to shortages and delays in drug production, further complicating the already challenging landscape of healthcare delivery. In light of these developments, pharmaceutical companies may need to reassess their strategies, potentially shifting production locations or increasing domestic sourcing to mitigate risks associated with trade volatility. Investors should remain vigilant, as the evolving trade dynamics could influence stock valuations within the sector, particularly for companies heavily reliant on cross-border trade. As the situation unfolds, the pharmaceutical industry will be closely monitoring policy changes and seeking ways to adapt to the shifting trade landscape.

• Improved Neubauer Chamber Slides Market Outlook to 2035
  Market Outlook · Sep 9, 2026

  The Neubauer chamber slides market is projected to experience significant growth through 2035, driven by advancements in laboratory technology and an increasing demand for precise cell counting in various research and clinical applications. The rising prevalence of chronic diseases and the growing emphasis on early diagnosis are key factors contributing to this positive outlook. As healthcare providers and research institutions continue to prioritize accurate and efficient diagnostic tools, the Neubauer chamber slides are expected to remain a staple in laboratories worldwide. Market analysts anticipate that the introduction of innovative designs and materials will enhance the functionality and usability of Neubauer chamber slides, further boosting their adoption. Additionally, the expansion of biotechnology and pharmaceutical sectors, particularly in emerging markets, is likely to create new opportunities for manufacturers. As competition intensifies, companies may focus on product differentiation and strategic partnerships to capture a larger share of the market. Investors and stakeholders should monitor these trends closely, as the growth of the Neubauer chamber slides market could have broader implications for the laboratory equipment sector. Increased demand may lead to heightened investments in research and development, ultimately fostering technological advancements that benefit the healthcare industry as a whole.

• Tracking cocoa may be just the beginning for PwC, Merck, Hashgraph provenance system
  CoinDesk · Sep 8, 2026

  PwC, Merck, and Hashgraph have launched an integrated solution aimed at enhancing the traceability and transparency of cocoa supply chains. This innovative system combines physical authentication methods with Hedera-powered blockchain technology, allowing stakeholders to track cocoa from farm to consumer. The initiative seeks to address growing concerns over quality assurance and compliance in the cocoa industry, which has faced scrutiny over sustainability and ethical sourcing practices. The implications of this development extend beyond the cocoa sector, as it showcases the potential for blockchain technology to transform supply chain management across various industries. By leveraging decentralized ledger technology, companies can improve accountability and transparency, which are increasingly demanded by consumers and regulators alike. As businesses look to adopt similar solutions, the partnership between PwC, Merck, and Hashgraph could set a precedent for future collaborations that prioritize ethical sourcing and product integrity. Market analysts suggest that this move could bolster investor confidence in companies that prioritize transparency and sustainability. As consumers become more conscious of the origins of their products, businesses that adopt such traceability systems may gain a competitive edge. Furthermore, the success of this cocoa initiative could encourage broader adoption of blockchain solutions in other sectors, potentially leading to a ripple effect that enhances overall supply chain resilience and trust.

• Pharma stocks soar as investors seek AI alternatives
  FT Companies · Aug 30, 2026

  Pharmaceutical stocks have experienced a significant surge in recent months, with many companies reaching record highs in August. This upward trend is largely attributed to a strategic shift among investors who are increasingly looking for alternatives to the volatile artificial intelligence sector. The positive momentum in the pharma industry has been further fueled by promising clinical trial results, which have instilled confidence in the potential for new drug approvals and market expansions. As investors pivot towards pharmaceuticals, the sector has become a beacon of stability amid broader market fluctuations. Analysts suggest that the robust performance of drugmakers could be indicative of a longer-term trend, as the demand for innovative therapies continues to grow. This shift not only reflects a desire for diversification but also highlights the resilience of the healthcare sector in times of economic uncertainty. With ongoing advancements in biotechnology and increased investment in research and development, pharmaceutical companies are well-positioned to capitalize on this renewed interest, potentially leading to sustained growth in stock valuations.

• Aggregate Retention Filter Underlayers Market Outlook to 2035
  Market Outlook · Aug 30, 2026

  The Aggregate Retention Filter Underlayers market is poised for significant growth, driven primarily by the increasing demand for stringent drainage solutions in electronics and semiconductor cleanroom infrastructures. With an estimated annual growth rate of 4-6% projected through 2035, the market is expected to see substantial expansion as industries prioritize high-quality filtration systems to meet regulatory standards and operational efficiency. The broader filtration market, which surpassed USD 53.5 billion in 2025, is also on an upward trajectory, with a compound annual growth rate (CAGR) of 4.2% anticipated until 2035. This growth is largely attributed to heightened investments in drug manufacturing and biotechnology research, both of which require ultra-pure environments that can only be achieved through advanced filtration technologies. As the demand for premium-grade underlayers, certified for high performance, continues to rise, manufacturers are likely to focus on innovation and quality to capture market share. Market analysts suggest that the Aggregate Retention Filter Underlayers segment will benefit from the overall expansion of the filtration market, particularly as sectors such as pharmaceuticals and electronics increasingly rely on advanced filtration solutions. This trend could lead to increased competition among manufacturers, driving technological advancements and potentially lowering costs for end-users over time. As the market evolves, stakeholders will need to stay attuned to regulatory changes and technological advancements that could shape future demand dynamics.

• Minnesota companies on pace for record year in acquisition deals
  IPO & M&A · Aug 28, 2026

  Minnesota companies are on track for a record year in acquisition deals, driven by a notable surge in mega-deals, including Bio-Techne's recent $11.3 billion acquisition by Merck. This transaction not only underscores the growing appetite for consolidation within the biotechnology sector but also positions Minnesota as a key player in the national M&A landscape. The state's robust life sciences industry, combined with favorable market conditions, has created an environment ripe for significant corporate transactions. The uptick in acquisition activity is reflective of broader trends in the market, where companies are increasingly seeking to enhance their competitive edge through strategic mergers and acquisitions. Analysts suggest that the ongoing interest from larger firms in acquiring innovative companies is likely to continue, potentially leading to further consolidation in various sectors. As Minnesota companies capitalize on this momentum, the implications for local economies and job markets could be substantial, with increased investment and growth opportunities on the horizon. Investors and stakeholders will be closely monitoring these developments, as they may signal shifts in market dynamics and corporate strategies moving forward.

• Big Pharma steps up fight against counterfeit weight-loss drugs
  FT Companies · Aug 28, 2026

  Major pharmaceutical companies are intensifying their efforts to combat the growing prevalence of counterfeit weight-loss drugs in the UK, driven by soaring consumer demand for effective weight management solutions. The surge in demand has created a lucrative market for counterfeiters, prompting leading drugmakers to implement stricter measures to protect consumers and their brand integrity. These initiatives include enhanced monitoring of online sales channels, partnerships with regulatory authorities, and the development of advanced authentication technologies to distinguish genuine products from fakes. The implications for the pharmaceutical market are significant. As counterfeit products pose not only a financial risk but also a potential health hazard to consumers, the industry's proactive stance may bolster public trust in legitimate weight-loss treatments. This could lead to increased sales for reputable companies as consumers become more cautious and discerning in their purchasing decisions. Furthermore, the heightened focus on combating counterfeit drugs may spur innovation in product development and marketing strategies, as companies seek to differentiate their offerings in a crowded marketplace. Overall, the fight against counterfeit weight-loss drugs reflects broader trends in consumer protection and regulatory compliance within the pharmaceutical sector.

• Single Use Filtration Assemblies Market Outlook Signals Expansion To $11.76 Billion Through 2030
  Market Outlook · Aug 26, 2026

  The single-use filtration assemblies market is projected to expand significantly, reaching an estimated value of $11.76 billion by 2030. This growth is driven by the increasing demand for biopharmaceutical production, where single-use technologies are favored for their efficiency and reduced risk of cross-contamination. The shift towards disposable systems is also being propelled by the need for cost-effective solutions in manufacturing processes, particularly in the wake of the COVID-19 pandemic, which highlighted the importance of flexibility and rapid response in production capabilities. Market analysts suggest that the rise in biopharmaceuticals, coupled with advancements in filtration technologies, will further enhance the adoption of single-use assemblies. Key players in the market are investing in research and development to innovate and improve product offerings, which is likely to create a competitive landscape. Additionally, regulatory support for single-use systems is expected to bolster market growth, as these solutions align with the industry's push for sustainability and efficiency. As the market evolves, stakeholders should monitor trends in biopharmaceutical production and regulatory changes that could impact the adoption of single-use filtration technologies. Investors may find opportunities in companies that are leading the charge in innovation and sustainability within this sector, as the demand for single-use systems is anticipated to remain robust in the coming years.

• FAQ: The Strategic and Regulatory Logic Behind Biopharma M&A, From Deal Pricing to IND Sponsorship
  IPO & M&A · Aug 26, 2026

  The biopharmaceutical sector has witnessed a surge in mergers and acquisitions (M&A) activity, driven by a combination of strategic imperatives and regulatory considerations. Companies are increasingly looking to consolidate their portfolios to enhance research capabilities, expand market access, and accelerate the development of innovative therapies. Deal pricing has become a critical factor, with valuations often reflecting not only the current pipeline potential but also the anticipated regulatory hurdles and market dynamics. Regulatory frameworks play a significant role in shaping M&A strategies within the biopharma industry. The process of Investigational New Drug (IND) sponsorship is a key consideration for companies evaluating potential acquisitions. Firms are keenly aware that the ability to navigate the complex regulatory landscape can significantly impact the success of drug development and commercialization. As a result, acquiring companies often seek targets with established regulatory pathways or promising candidates that align with their strategic goals. Market implications of these trends are profound. Increased consolidation can lead to reduced competition, potentially impacting drug pricing and availability. Conversely, successful mergers can result in enhanced innovation, as combined resources may lead to more robust R&D efforts. Investors are closely monitoring these developments, as the outcomes of biopharma M&A activity will likely influence stock valuations and the overall health of the sector in the coming years.

All 46 articles in the app →

Index membership

• Dow Jones Industrial Average · Health Care
• S&P 500 · Health Care

Related Health Care stocks

• AMGNAmgen
• JNJJohnson & Johnson
• UNHUnitedHealth Group